New User:

Forgot your password?

Stock Market & Financial Investment News

News Breaks
December 17, 2013
09:19 EDTAMGNAmgen announces MENDEL-2 Phase 3 trial met co-primary endpoints
Amgen announced that the Phase 3 MENDEL-2 trial with evolocumab met its co-primary endpoints, which was the percent reduction from baseline in low-density lipoprotein cholesterol at week 12 and the mean percent reduction from baseline in LDL-C at weeks 10 and 12. The mean percent reductions in LDL-C, or "bad" cholesterol, compared to placebo and ezetimibe were consistent with results observed in the MENDEL Phase 2 study. Safety was balanced across treatment groups. The most common adverse events were headache, diarrhea, nausea and urinary tract infection. Details of the MENDEL-2 study results will be submitted to a future medical conference and for publication.
News For AMGN From The Last 14 Days
Check below for free stories on AMGN the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 8, 2014
11:03 EDTAMGNPiper Jaffray's biopharm analyst holds an analyst/industry conference call
Biopharm Analyst Schimmer discusses PCSK9 Inhibitors and other atherosclerosis approaches on an Analyst/Industry conference call. Relevant companies AEGR, ALNY, AMGN, ARNA, AZN, BMY, CBST, LLY, ESPR, GSK, ICPT, ISIS, MNKD, MRK, OREX, PFE, REGN, RHHBY, SNY and VVUS may be included on the Analyst/Industry conference call to be held on April 10 at 3 pm.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the disclaimer & terms of use